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Abstract
Monozygotic (MZ) twin pair discordance for childhood-onset Type 1 Diabetes (T1D) is ,50%, implicating roles for genetic
and non-genetic factors in the aetiology of this complex autoimmune disease. Although significant progress has been made
in elucidating the genetics of T1D in recent years, the non-genetic component has remained poorly defined. We
hypothesized that epigenetic variation could underlie some of the non-genetic component of T1D aetiology and, thus,
performed an epigenome-wide association study (EWAS) for this disease. We generated genome-wide DNA methylation
profiles of purified CD14+ monocytes (an immune effector cell type relevant to T1D pathogenesis) from 15 T1D–discordant
MZ twin pairs. This identified 132 different CpG sites at which the direction of the intra-MZ pair DNA methylation difference
significantly correlated with the diabetic state, i.e. T1D–associated methylation variable positions (T1D–MVPs). We
confirmed these T1D–MVPs display statistically significant intra-MZ pair DNA methylation differences in the expected
direction in an independent set of T1D–discordant MZ pairs (P = 0.035). Then, to establish the temporal origins of the T1D–
MVPs, we generated two further genome-wide datasets and established that, when compared with controls, T1D–MVPs are
enriched in singletons both before (P = 0.001) and at (P = 0.015) disease diagnosis, and also in singletons positive for
diabetes-associated autoantibodies but disease-free even after 12 years follow-up (P = 0.0023). Combined, these results
suggest that T1D–MVPs arise very early in the etiological process that leads to overt T1D. Our EWAS of T1D represents an
important contribution toward understanding the etiological role of epigenetic variation in type 1 diabetes, and it is also the
first systematic analysis of the temporal origins of disease-associated epigenetic variation for any human complex disease.
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Introduction
Type 1 diabetes (T1D) is a complex autoimmune disease
affecting more than 30 million people worldwide [1]. It is caused
by a combination of genetic and non-genetic factors [1–3], leading
to immune destruction of insulin-secreting islet cells. A role for
non-genetic factors is suggested by studies of migrant populations,
the recent rise in T1D prevalence, and twin-cohorts [3,4]. For
example, a monozygotic (MZ) twin of a T1D–affected co-twin will
not always develop the disease, only ,50% do so, even though
MZ twins are genetically identical [3,5,6]. It has been proposed
that these non-genetic factors could take the form of environmen-
tal influences such as viral infections, dietary factors, or vitamin D
deficiency [7]. However, none of these have been conclusively
proven to play a role in T1D etiology and compared with the
recent progress in elucidating T1D–associated genetic variants,
non-genetic factors have remained poorly defined.
We therefore hypothesized that epigenetic variation contributes
to the non-genetic component of T1D etiology. Epigenetic
modifications, such as DNA methylation and post-translational
histone modifications, are indispensable for a variety of genomic
processes including transcriptional regulation and maintenance of
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genomic integrity [8]. Their importance is further highlighted by
the association between epigenetic perturbations and cancer [8].
More recently, and relevant to our hypothesis that T1D
aetiopathogenesis has an epigenetic component, it has been found
that epigenetic perturbations are also associated with non-
malignant diseases, including autoimmune conditions, and that
MZ twins can be epigenetically discordant i.e. epigenetic variation
can exist in the absence of genetic heterogeneity [9–15]. We
therefore decided to perform an epigenome-wide association study
(EWAS) to identify epigenetic variation that, in combination with
genes and environment, could alter T1D susceptibility by
potentially influencing the functions of key immune effector cells,
given that the majority of known T1D–associated genetic variants
are in, or near, genes that predominantly function in such cell
types [5]. Importantly, we wanted to rule out genetic differences as
the basis of any identified T1D–associated epigenetic variation,
and also better understand whether such epigenetic variants are
potentially causal for, or consequential to, the disease process.
Making these distinctions is critical for subsequent elucidation of
the etiological role of disease-associated epigenetic variation. We
therefore devised a novel EWAS strategy that combines T1D–
discordant MZ twins with longitudinally sampled pre–T1D
singletons to rule out genetic differences and establish the temporal
origins of T1D–associated epigenetic variation.
Results
Identification of T1D–associated DNA methylation
variable positions (T1D–MVPs)
For the initial genome-wide screen, we recruited 15 T1D–
discordant MZ twin pairs (Table S1), selected according to the
following criteria: (i) European origin; (ii) both co-twins available
for study; (iii) diabetic twin had T1D diagnosed at ,20 years of
age; (iv) neither twin was receiving drugs other than human insulin
for the diabetic twin; (v) diabetic twin had no current major
diabetes complications; (vi) non-diabetic twin had low disease risk,
that is ,2% based on the lack of diabetes-associated autoanti-
bodies (GADA, I-A2A and ZnT8A), and normal glucose tolerance
[5,16]. From these twins, we isolated CD14+ monocytes for
subsequent DNA methylation analysis. Monocytes are immune
effector cells that give rise to tissue macrophages that have been
associated with the destruction of the islet cells, causing insulin
deficiency [17–19]. Furthermore, monocytes can be obtained to
.90% purity (Figure S1), thereby minimizing detection of
apparent epigenetic changes due to altered proportions of cell
subtypes (as might happen with whole blood), and loss of sensitivity
due to tissue-specificity of inter-individual epigenetic variation.
Finally, monocytes have a short lifespan of a few weeks, so are less
likely to harbor post-differentiation, random epigenetic alterations.
DNA methylation profiling was performed using Illumina
HumanMethylation27 BeadChips (Illumina 27K) [20], that allow
genome-wide single-CpG resolution DNA methylation measure-
ments at 27,458 different CpG sites within 14,475 promoters (per
promoter there are approximately 2 CpG sites usually spaced
between 500–2,000 bp apart), and correlate well with bisulfite
PCR sequencing (R2= 0.88, Figure S2).
Following array Q.C. and normalization, the final dataset
comprised of 22,645 (of the total 27,458) CpG sites (Materials and
Methods). We used Wilcoxon signed rank tests to identify T1D–
associated intra-pair DNA methylation differences at each CpG
site i.e. T1D–associated methylation variable positions (T1D–
MVPs). This statistical procedure tests the null hypothesis that
there is no intra-twin pair difference in methylation, and also takes
into account the arrangement of genetically identical T1D–
affected and healthy individuals into T1D–discordant MZ twin
pairs. At P,0.01 – a pragmatic threshold for selecting CpG sites
for further study – we identified 58 T1D–MVPs hypermethylated
(hyperT1D–MVPs), and 74 T1D–MVPs hypomethylated (hy-
poT1D–MVPs) in the T1D–affected co-twins (Table S2). The
number of MVPs observed at this threshold was significantly
higher than would be expected by chance (P= 0.02). Mean intra-
pair differences in DNA methylation levels at T1D–MVPs ranged
from 0.13%–6.6% (Figure 1A and Table S2), in line with recent
findings that inter-individual epigenetic variation in the context of
human non-malignant complex diseases and phenotypes is almost
invariably of small magnitude [9–15].
Examination of CpGs neighboring the ‘index’ T1D–MVPs
revealed that they showed similar directional DNA methylation
differences, although just short of significance (P = 0.06, Figure 1B).
The power to perform this type of analysis using the Illumina27K
platform is somewhat limited since the spacing between the two
different CpG sites per promoter, in the majority of cases, is
greater than the 500 bp range over which correlation of DNA
methylation has previously been reported to decay [21].
Therefore, although not conclusive, our analysis suggests that at
least T1D–MVPs are likely to be within larger T1D–associated
differentially methylated regions (DMRs).
T1D–MVPs display decreased intra-pair variability in
control MZ pairs
As with any microarray-based platform, different probes on the
Illumina27K array are associated with inherently different levels of
technical variability, or experimental noise. Additionally, it is
known that some CpG sites in the human genome are intrinsically
epigenetically metastable, that is, they display elevated levels of
inter-individual variation that is not explained by genetic
heterogeneity [11]. To test whether these sources of technical or
biological ‘noise’ potentially influence our results, we generated
Illumina27K profiles for CD14+ cells from 9 different control MZ
pairs (i.e. both co-twins are T1D–unaffected). We calculated intra-
Author Summary
Type 1 diabetes (T1D) is a complex autoimmune disease
affecting .30 million people worldwide. It is caused by a
combination of genetic and non-genetic factors, leading to
destruction of insulin-secreting cells. Although significant
progress has recently been made in elucidating the
genetics of T1D, the non-genetic component has remained
poorly defined. Epigenetic modifications, such as methyl-
ation of DNA, are indispensable for genomic processes
such as transcriptional regulation and are frequently
perturbed in human disease. We therefore hypothesized
that epigenetic variation could underlie some of the non-
genetic component of T1D aetiology, and we performed a
genome-wide DNA methylation analysis of a specific
subset of immune cells (monocytes) from monozygotic
twins discordant for T1D. This revealed the presence of
T1D–specific methylation variable positions (T1D–MVPs) in
the T1D–affected co-twins. Since these T1D–MVPs were
found in MZ twins, they cannot be due to genetic
differences. Additional experiments revealed that some
of these T1D–MVPs are found in individuals before T1D
diagnosis, suggesting they arise very early in the process
that leads to overt T1D and are not simply due to post-
disease associated factors (e.g. medication or long-term
metabolic changes). T1D–MVPs may thus potentially
represent a previously unappreciated, and important,
component of type 1 diabetes risk.
T1D Epigenetics
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MZ pair methylation differences at each probe on the Illumi-
na27K array, for each of the 9 different MZ pairs, and then
calculated the variance observed in intra-MZ pair methylation
differences at each probe over all 9 MZ pairs (Figure 2). We found
that the range of intra-MZ pair variability at T1D–MVP-
corresponding probes is significantly less compared with the range
of variability observed across other probes in the control MZ pairs
(P = 2.461028, Welch’s t-test). Although this analysis does not
distinguish between technical and biological variance, it does
strongly suggest that the measured intra-MZ pair methylation
differences at T1D–MVPs are not simply the result of higher-than-
average levels of technical or biological noise.
Pyrosequencing-based analysis and independent
biological confirmation of T1D–MVPs
We then attempted to confirm the T1D–MVPs using two
approaches: pyrosequencing-based bisulfite PCR analysis, and also
array-based biological confirmation in an independent set of
T1D–discordant twins. For the pyrosequencing, we randomly
chose 24 different T1D–MVPs – 16 hyperT1D–MVPs and 8
hypoT1D–MVPs. These were assayed in CD14+ cells from each of
15 different T1D–discordant MZ pairs (10 from the original 15
used in the Illumina27K screen, and 5 additional pairs), i.e. a total
720 different pyrosequencing reactions performed according to
standard procedures (Materials and Methods). We obtained
complete data for all samples for 13 amplicons corresponding to
5 hyper-MVPs and 8 hypo-MVPs (all raw data are shown in Table
S3). A group-wise analysis of these 13 amplicons revealed that
hyperT1D–MVPs displayed an overall trend towards greater
methylation levels in the affected co-twins compared with
hypoT1D–MVPs, although this difference was just short of
significance (P = 0.063, Welch’s t-test, Figure S3).
Keeping in mind that the T1D–MVPs displayed intra-pair
methylation differences of ,5%, and that pyrosequencing is
limited to identifying inter-sample methylation differences of .5%
[22], and not amenable to simultaneously analyzing a large
number of different genomic regions, we reasoned that a genome-
scale approach would provide greater power for confirming the
original T1D–MVPs. Furthermore, confirmation in an indepen-
dent set of samples would be strong support for the T1D–MVPs
being bona fide T1D–assocated epigenetic perturbations. There-
fore, as independent biological confirmation of the T1D–MVPs,
we performed Illumina27K profiling on CD14+ cells obtained
from 4 additional T1D–discordant MZ pairs that were not
included in the original Illumina27K screen of 15 T1D–discordant
MZ pairs. Although this number of MZ pairs is too small to
perform de novo T1D–MVP identification, it can be used to test
whether the T1D–MVPs found in the first screen show intra-MZ
pair DNA methylation differences in the expected direction.
Indeed, we observed a statistically significant DNA methylation
difference in the expected direction between hyper and hypoT1D–
MVPs in these 4 additional pairs (P = 0.0375, Welch’s t-test,
Figure 3), thus providing biological confirmation of the original
T1D–MVP calls.
The successful confirmation of the T1D–MVPs by Illumina27K
chips in an independent set of T1D–discordant MZ twins (i.e.
genetically identical co-twins) is unlikely to be due to a platform-
specific bias. The co-twins for each twin pair were recruited and
Figure 1. Identification of Type 1 Diabetes-associated DNAmethylation variable positions (T1D–MVPs). (A) On the x-axis, each ‘column’
of data contains 15 different points, indicating the absolute intra-pair DNA methylation difference observed at a single T1D–MVP for each of the 15
different T1D–discordant MZ pairs. Plotted are the 58 different hyper- and 74 different hypoT1D–MVPs that were called at P,0.01. Data are arranged
in order of decreasing or increasing absolute intra-MZ pair methylation differences for hypo- (yellow) and hyper- (blue) T1D–MVPs respectively (Refer
to Table S2 for numerical values). (B) For each T1D–MVP, we asked whether experimental data is available for a neighboring CpG site within 2 kb
genomic distance. In cases where several such CpG sites were present, we considered only the closest neighbor. These data were available for 56
Hypo-T1D–MVPs (out of total 74) and for 39 Hyper-T1D–MVPs (out of total 58). We then quantified the T1D–specific methylation change of these
neighboring CpG sites, and plotted the intervals, such that boxes cover 50% and whiskers 95% of the data range.
doi:10.1371/journal.pgen.1002300.g001
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sampled at the same time, their blood processed simultaneously,
and all samples arrayed randomly on the Illumina27K chips. In
our opinion, the more likely conclusion is that the T1D–MVP
signature is real but of small magnitude, and hence standard
bisulfite PCR sequencing-based methods routinely applied for
validating methylation differences of relatively larger magnitudes
may not be appropriate. Although currently not in routine use,
targeted deep coverage high throughput sequencing-based bisulfite
sequencing may be a better option for technical validation in
future such studies.
T1D–MVPs are associated with several genes involved in
immune function
Each of the 132 different T1D–MVPs is associated with a different
gene. Although this number of genes is too small for performing a
robust Gene Ontology or pathway analysis, we note that T1D–MVP
associated genes or gene products include several known to be
associated with T1D or immune responses (Table S2). This includes,
the HLA class II gene, HLA-DQB1, which carries the highest single
genetic risk for T1D (along with HLA-DRB1) [23], RFXAP, an HLA
class II regulating element, NFKB1A, an important regulator of
apoptosis and inflammatory immune responses, TNF, a key
inflammatory cytokine associated with T1D in animal models, and
GAD2which encodes GAD65, a major T1D autoantigen involved in
disease etiology [24]. Identification of GAD2 indicates that we have
identified T1D–associated MVPs, and not just an epigenetic
signature associated with a non-specific immune response. Also,
the T1D–MVPs do not overlap those reported recently for systemic
lupus erythematosis in 5 disease-discordant MZ twin pairs [10].
T1D–MVPs are found in singletons that harbor T1D–
associated autoantibodies before disease diagnosis
The above data do not distinguish among MVPs present before
overt T1D, and those caused by insulin treatment or by the disease
process after clinical diagnosis. Without making this distinction, it
would not be possible to consider T1D–MVPs as potentially
causative of the disease. The identification of the temporal origins
of disease-associated epigenetic variation thus represents an issue
of fundamental importance, but has never previously been
addressed in any complex disease epigenomic study [e.g. Refs.
9–15]]. To address this issue in the context of T1D, we generated
Illumina27K-based DNA methylation profiles for CD14+ cells
obtained from 7 singletons before and immediately after they
presented with clinical T1D. These 7 individuals were recruited
from a cohort of healthy school children and young adults of
European origin in Alb-Donau County, Germany, all without a
family history of T1D [25]. All ‘pre–T1D’ samples were obtained
when these individuals had diabetes-associated autoantibodies
(GAD65, IA2 and Islet Cell Antibodies), but with normal blood
glucose levels and without insulin treatment. We used 9 normal
MZ twins pairs as independent controls, since they had not been
used for the initial MVP calling. We found that in both pre– and
post–T1D samples relative to controls, the same T1D–MVPs
display methylation differences in the expected direction
(P= 0.015) (Figure 4A and Table S4). Specifically, 71% and
66% of T1D–MVPs showed the expected directionality in pre- vs.
control and post- vs. control comparisons respectively. There was
no significant difference in T1D–MVP methylation levels between
the pre- and post–T1D samples (P.0.6). These results: (i) provide
Figure 2. T1D–MVPs are not due to increased technical and/or biological variability. We generated Illumina27K profiles for CD14+ cells
from 9 different control MZ pairs and calculated intra-MZ pair methylation differences at each probe on the Illumina27K array, for each of the 9
different MZ pairs. Here we plot the variance (around the mean) observed in intra-MZ pair methylation differences at each probe over all 9 MZ pairs
(i.e. each ‘column’ of data contains 9 different data-points). For each MZ pair, the choice of the ‘index’ co-twin was arbitrary. CpG sites were ranked in
order of increasing sample variance across the 9 intra-pair differences measured at each site. The range of intra-MZ pair variability at T1D–MVP-
corresponding probes (highlighted) is significantly less compared with the range of variability observed across other probes on the array
(P = 2.461028, Welch’s t-test). Number of probes used in this analysis = 22,645 (of the total 27,458 probes on the array. Refer to the section ‘Array
Processing’ in Materials and Methods for the Q.C. steps performed on the arrays).
doi:10.1371/journal.pgen.1002300.g002
T1D Epigenetics
PLoS Genetics | www.plosgenetics.org 4 September 2011 | Volume 7 | Issue 9 | e1002300
further independent biological confirmation of the original T1D–
MVPs (in addition to the 4 different T1D–discordant MZ pairs
described above); (ii) demonstrate that T1D–MVPs precede
clinical diagnosis; (iii) and show that T1D–MVPs can be identified
in the context of normoglycaemia, independent of the disease
process, metabolic dysfunction, pharmacological or insulin
treatment, or the twinning event since the replication was
performed in singletons. It is also important to note that since
T1D–MVPs are found both before, and following, T1D–onset
within the same individuals, but with no significant difference
between pre- vs. post- T1D–onset profiles, we can conclude that at
least some T1D–MVPs are temporally stable over many years.
The results described above do not rule out the possibility that
T1D–MVPs arise as a result of the sub-clinical autoimmune
process that leads to clinical T1D. We therefore performed
Illumina27K analysis of 4 different singletons that, at the time of
sampling, were autoantibody positive but had still not developed
T1D even after 12 years follow up (i.e. Ab+/T1D–, Materials and
Methods). Although autoantibody positivity can predict progres-
sion to T1D (about 50% progression by 5 years), the longer an
individual stays disease-free the lower that risk. The risk of
progression to T1D after 12 years from detection of autoantibody
positivity estimated at ,5% [26]. In a comparison with the same
controls used in the analysis of the pre-/post–T1D samples
(described above), we found T1D–MVPs to be enriched in the
Ab+/T1D–samples (P = 0.0023, Welch t-test, Figure 4B). Specif-
ically, 67% of T1D–MVPs in the Ab+/T1D–singletons, relative to
controls, showed directionality consistent with the original calls.
This analysis limits the temporal origins of T1D–MVPs to two
possibilities. First, they could arise as a result of the autoimmune
process associated with the appearance of autoantibodies in the
pre–T1D phase, though this process would not be required for
persistence of T1D–MVPs, as autoantibodies are infrequent in
long-standing T1D (in our study, only 2/15 diabetic co-twins were
autoantibody positive at time of sampling). Alternatively, the
appearance of T1D–MVPs and autoantibodies could reflect
distinct processes. In either case, T1D–MVPs must arise very
early in the course of events that lead to clinical T1D.
Discussion
Disentangling epigenetic effects from the confounding influ-
ences of genetic and/or environmental heterogeneity represents
Figure 3. Biological confirmation of the T1D–MVPs in an
independent set of T1D–discordant MZ pairs. Mean intra-pair
methylation differences associated with T1D–MVPs between 4 T1D–
discordant MZ pairs not included in the original dataset. Bars indicate
50% bootstrap confidence intervals on the means, and whiskers
indicate 95% confidence intervals on the means. We observed a
statistically significant DNA methylation difference in the expected
direction between hyper and hypoT1D–MVPs (P = 0.0375, Welch’s
t-test).
doi:10.1371/journal.pgen.1002300.g003
Figure 4. Establishment of the temporal origins and additional independent biological confirmation of the T1D–MVPs. (A) Boxplots
of the mean difference in the proportion of CpG sites methylated (%) between 7 pre- or post–T1D diagnosis samples and 18 controls from 9
unaffected MZ pairs or between pre- and post–T1D diagnosis samples at 74 hypo- and 58 hyper-methylated MVPs. Bars indicate 50% bootstrap
confidence intervals on the means, and whiskers indicate 95% confidence intervals on the means. (B) Boxplots of the mean difference in the
proportion of CpG sites methylated (%) between each of 4 Ab+/T1D–singletons and the same controls as in ‘A’. Bars indicate 50% bootstrap
confidence intervals on the means, and whiskers indicate 95% confidence intervals on the means.
doi:10.1371/journal.pgen.1002300.g004
T1D Epigenetics
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a significant barrier to elucidating the etiological role of
epigenetic variation in human complex disease. Herein lies the
key advance made by our study, as the T1D–MVPs we report
here represent the first example of disease-associated epigenetic
variation that antedates clinical disease and cannot be explained
by genetic heterogeneity, pharmacological treatment, or post-
disease cellular dysfunction. Our results provide a platform from
which to address several key issues in future studies that we
discuss below.
First is the issue of causality. In GWASs, any disease-associated
genetic variant is, or linked to, a causative variant. In EWASs, on
the other hand, the direction of the cause-consequence relation-
ship is difficult to define if an appropriate study design is not
employed. Specifically, the commonly used unrelated singleton
‘‘case versus control’’ design of GWAS is not appropriate as
epigenetic variation found to be associated with the disease could
simply be due to the disease process itself or disease-associated
genetic variation. It is for this reason that we employed the study
design described here: T1D–discordant MZ twin pairs combined
with longitudinally sampled pre–T1D singletons to rule out genetic
differences and establish the temporal origins of T1D–associated
epigenetic variation. Using this approach, we were able to
demonstrate that T1D–MVPs antedate clinical disease. However,
it will be important to further explore the temporal origins of the
T1D–MVPs by analyzing samples obtained before the appearance
of T1D–associated autoantibodies, which could help determine
whether T1D–MVPs arise even before the sub-clinical immune
phase. In this regard, longitudinal birth cohorts will be invaluable
[27]. If some T1D–MVPs were found before the sub-clinical
immune autoantibody response, then the hypothesis that these
T1D–MVPs are causing disease would be strengthened. The
identification of T1D–MVPs in individuals before the appearance
of T1D–associated autoantibodies would exclude T1D–MVPs
being simply secondary to the autoantibody-associated immune
process.
Establishing the temporal origins of T1D–MVPs will also be
useful for elucidating the biological origins of T1D–MVPs. For
example, if there were evidence that T1D–MVPs exist at birth
(e.g. from birth-cohort studies), then this would suggest stochastic
or environmental factors that operate in utero. Given that we have
studied MZ twins—genetically identical individuals exposed to
similar environments during childhood—early life stochastic
origins of T1D–MVPs is an attractive idea. Indeed, stochastic
epigenetic variation in humans is more common than previously
appreciated as demonstrated by the recent genome-scale analysis
of DNA methylation profiles in 114 monozygotic (MZ) and 80
dizygotic (DZ) twins [11]. A potential source of stochastic
epigenetic variation could be genetic variants that increase the
probability of stochastic epigenetic variation in cis, as suggested
by various authors [28–30]. In the context of our results, it
doesn’t mean that T1D–MVPs are due to somatic genetic
differences, but rather the T1D–discordant twins may harbor
germline genetic variants that are associated with increased
levels of epigenetic stochasticity, and indeed we find that T1D–
MVPs are less epigenetically variable in the normal MZ twins
(Figure 2). If this occurs in the context of a genomic background
that is predisposed to a given disease, then it could impact on the
probability of one twin developing the disease, whereas the co-
twin remains disease-free. However, it is also possible that T1D–
MVPs are induced environmentally as MZ twins are exposed to
similar, but not identical, environments and there are examples
of disease-relevant environmental factors that operate in early
life to influence disease-risk [31]. Given a large enough sample
size and genome-coverage, it might be possible to identify
environmental triggers based on gene regulatory networks
enriched for T1D–associated epigenetic and transcriptional
variation.
Third, although we have focused on promoter-associated
single CpGs here, our data suggest that larger surrounding
genomic regions are affected (i.e. differentially methylated
regions or DMRs), and it will be important to further define
these regions spatially. In the near future, it should be possible to
perform high throughput sequencing-based whole-genome DNA
methylomic profiling in large cohorts to: (i) identify new T1D–
MVPs/DMRs, including those that might exist outside of
promoter regions; (ii) help define the boundaries of the T1D–
associated DMRs, if they exist; (iii) establish the hierarchy of
CpG sites within a DMR in terms of functional impact, that is, it
is possible we have identified T1D–MVPs that are ‘linked’ to the
most discriminative CpG site i.e. a ‘tag’-MVP, similar to tag-
SNPs in GWASs; (iv) profile a number of key cell types including
other immune effector cells.
Fourth, we need to understand the functional outcome of T1D–
MVPs at the molecular level. The most obvious impact is on gene
expression, but equally important will be investigations into how
the MVPs alter the local chromatin structure. For example, do
they alter the binding of key transcription factors? Or do they
correlate with alterations in other epigenetic marks such as histone
modifications? The magnitude of methylation differences we have
identified at T1D–MVPs is relatively small compared with DNA
methylation perturbations generally observed in the context of
cancer. However, given that other small-scale studies of non-
malignant disease-associated methylation variation in humans also
report effects of small magnitude [10–15], it is quite possible that
this is the norm for complex disease-associated epigenomic
variation. In this regard, it is worth drawing parallels with findings
from GWAS in which most variants individually confer a small
disease-risk [32]. Therefore, studying the local chromatin
architecture and gene expression will help define how DNA
methylation variants of small magnitude impact on molecular
outcomes in a variety of key immune effector cells, thus helping to
elucidate how T1D–MVPs, in combination with genetic and other
environmental factors, are involved in T1D etiology and the causal
or consequential nature of the T1D–MVPs. Of course, it is also
quite possible that some T1D–MVPs are not directly involved in
the T1D pathogenesis process, but rather are biomarkers for the
disease. This is similar to T1D–associated GAD65, IA2 and islet
cell autoantibodies, which are highly predictive of disease, but
without evidence that they are involved in T1D etiology. Analysis
of individuals before they present with autoantibodies will be key
to establishing whether T1D–MVPs are valuable biomarkers for
the disease that can augment the predictive power of autoanti-
bodies and genetic variants.
It is noteworthy that a T1D–MVP signature was detected by
assaying a relatively modest number of samples and genome
coverage, which emphasizes the power of our study design that
combines MZ twins and prospectively sampled individuals, as
opposed to the typical singleton ‘case versus control’ approach.
Although previous complex disease epigenomic studies have
correlated disease-associated epigenetic variants with changes in
gene expression or temporal stability [10–15], none have been
able to address the key question of temporal origins, which is
critical for establishing the direction of the cause-consequence
relationship between disease phenotype and epigenetic variation.
Therefore, in addition to identifying a previously unappreciated
molecular component of type 1 diabetes risk, we believe our study
also represents one possible blueprint for future EWASs of other
complex diseases [33].
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Materials and Methods
Processing of monozygotic twin samples
Monozygotic twin pairs were selected from the British Diabetic
Twin Study (Table S1) [34]. Twins are ascertained by referral
through their physicians. Twins were genotyped for HLA-DQB1
and -DRB1 using a sequence-specific oligonucleotide probe–based
method and line strips from Roche Molecular Systems. Diabetes-
associated autoantibodies were analyzed as described below.
Monozygosity was established using both clinical data and DNA
fingerprinting (data not shown). T1D was defined according to the
National Diabetes Data Group criteria and diabetes excluded in
the non-diabetic co-twins by a 75 g oral glucose tolerance test and
random whole blood glucose at testing less than 7.0 mmol/L [34].
All T1D patients were treated from diagnosis with insulin and take
highly purified human insulin at least twice daily. All subjects gave
informed consent and the study was approved by the Northern
and Yorkshire Research Ethics committee (REC Reference
Number: 06-MREO-3-22). PBMCs from subjects investigated
were prepared from heparinised blood using standard Ficoll-
Hypaque separation. After washing, PBMCs were counted using
the Naebaur counting chamber after staining with Trypan blue to
asses cell viability, and washed in PBS before isolation of CD14+
cells. Briefly PBMCs were washed with 10 ml MACS buffer and
CD14+ cells isolated according to manufacturer’s instruction using
positive selection MS column (Miltenyi Biotec, UK, # 130-042-
201). From each MACS-enriched CD14+ cell sample, we took two
aliquots (16105 cells in each case) and stained with either mouse
IgG as a negative control or CD14+ FITC. CD14+ percentage
purity was determined by FACS (Figure S1). Overall percentage
purity of CD14+ cells observed typically ranged from 90–95%.
CD14+ cells were then lysed for DNA extraction using Qiagen
method according to manufacturer’s instructions. The concentra-
tion of DNA was determined by using NanoDrop.
Processing of pre–T1D, post–T1D, and
Ab+/T1D–singletons
These singletons were recruited from a cohort of healthy school
children and young adults of European origin in Alb-Donau
County, Germany [31]. All subjects screened were without a
family history of T1D. Of 7287 children, 72 children had islet cell
autoantibodies and were followed prospectively. Of these 72, 10
developed T1D, of whom 7 had relevant blood samples available
for analysis both initially and at diagnosis (Table S1). Samples
were analyzed for HLA-A, HLA-B, HLA-DRB1 and HLA-DQB1
genotypes and diabetes-associated autoantibodies as for the MZ
twins. Blood was obtained from 7 subjects at two time points,
before and after T1D diagnosis, for replication of T1D–MVPs.
PBMCs were isolated from whole blood by standard Ficoll–
Hypaque density gradient centrifugation. Briefly, approximately
10 mL of heparinized, plasma-reduced blood was diluted with
Hank’s buffered salt solution (HBSS; 1:2 dilution). Then, 15 mL of
Ficoll was covered with a layer of diluted blood (30 mL). After
30 min of centrifugation (2000 rpm, room temperature), the
PBMCs could be easily collected. After two washing steps and
cell counting, the isolated PBMCs were frozen and stored in a
liquid nitrogen freezer. PBMCs were frozen in FBS containing
10% dimethylsulfoxide (DMSO). Several portions of a given blood
sample were frozen, typically a cryotube vial contained between 8–
12 million PBMC each. For the isolation of CD4+, CD8+ and
CD14+ cells, PBMCs were thawed and washed in 10 mL of
prewarmed PBS to remove all traces of the cryoprotectant in the
freezing medium. Cell viability was determined spectrophotomet-
rically using trypan blue staining. After thawing, cells were
obtained and stained with trypan blue solution 0.4%. Finally, at
least 200 cells were counted under the microscope. For magnetic
separation only cryo-preserved samples were used. Since Magnetic
beads may bind to dead cells non-specifically, only samples that
show a cell viability of more than 90% were analyzed. Using this
criterion of initially 20 PBMC samples 15% had to be excluded.
Cell viability as determined by trypan blue exclusion was not
dependent on storage time in liquid nitrogen. Magnetic separation
was performed according to the manufacturers specifications
(MACS, Miltenyi Biotec). To evaluate the efficiency and purity
(typically $95%) of the magnetic separation flow cytometry
analysis was performed after cell separation using standard
staining protocol for surface markers. All subjects gave informed
consent and the study was approved by the local ethical committee
(ref: 08/1990 & 07/1998).
T1D–associated autoantibodies
All twin samples were tested at a single laboratory (London) in
batched assays as previously described [33]. Positive results were
duplicated to limit the false positive rate to less than 0.2%. In the
latest 2010 Diabetes Antibody Standardization Program (DASP)
the London assay characteristics were: GADA sensitivity 82%,
specificity 86%; I-A2A, sensitivity 60%, specificity 98%; and
ZnT8A sensitivity 72%, specificity 88% (data unpublished). Islet
Cell autoantibodies was performed in Ulm, Germany in a batched
assay as described (30) and samples were also tested in London,
UK for GADA, I-A2A and ZnT8A [35]. Islet Cell autoantibodies
were measured by indirect immunofluorescence, with detection
limit 5 JDF units, and .20 JDF units as positive; assay sensitivity
and specificity was 100% in 13th Islet Cell Autoantibody
Workshop (1998); results were documented as positive or negative.
Array processing
Arrays were processed at the Barts and The London Genome
Centre, London, UK according to the manufacturer’s recommen-
dations. Methylation scores for each CpG site are called as ‘Beta’
values (using BeadStudio software from Illumina), that range from
0 (unmethylated, U) to 1 (fully methylated, M) on a continuous
scale, and are calculated from the intensity of the M and U alleles
as the ratio of fluorescent signals b =Max(M,0)/(Max(M,0)+-
Max(U,0+100). For many arrays, a small number of probes do not
yield sufficient signal for BeadStudio to make a Beta value score.
Samples where more than 5% of probe Beta values were missing
were discarded or repeated. We also checked the distribution of
Beta values for the expected bimodal distribution of Beta values,
and repeated arrays with ,10% of probe Beta values .=0.75.
We also discarded any probes for which a score was missing for
any array in the final set of arrays, and probes located on the X-
and Y-chromosomes. The final dataset therefore comprised of
22,645 (of the total 27,458) CpG sites. The raw Beta scores were
normalized using standard quantile normalization algorithms that
are available from https://github.com/dasmoth/metharray-
scripts.
Identification of T1D–MVPs
For each of the 22,645 CpG probes for which we had complete
data, normalized Beta scores from 15 diabetics were compared
with those from their normal twins using the Wilcoxon signed-rank
test. Given the sample size and number of probes under
consideration, it was not possible to reasonably correct for
multiple testing, so we adopted a pragmatic approach, using the
uncorrected p-values from this test as an indicator of possible
T1D–MVPs which were then validated by subsequent analyses.
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All probes with a Wilcoxon p-value,0.01 were considered to be
potential T1D–MVPs.
Pyrosequencing validation
One mg of DNA was bisulfite converted using the EpiTect-96
Bisulfite kit (Qiagen, Hilden, Germany) according to the
manufacturer’s instructions. Regions of interest for validation
were amplified using 30 ng of bisulfite treated human genomic
DNA and 5 to 7.5 pmol of forward and reverse primer, one of
them being biotinylated. Sequences for oligonucleotides for PCR
amplification and pyrosequencing are listed in Table S5. Reaction
conditions were 16 HotStar Taq buffer supplemented with
1.6 mM MgCl2, 100 mM dNTPs, and 2.0 U HotStar Taq
polymerase (Qiagen) in a 25 ml volume. The PCR consisted of a
denaturing step of 15 min at 95uC followed by 50 cycles of 30 s at
95uC, 30 s at the respective annealing temperature and 20 s at
72uC, with a final extension of 5 min at 72uC. 10 ml of PCR
product were rendered single-stranded and 4 pmol of the
respective sequencing primer were used for analysis. Quantitative
DNA methylation analysis was carried out on a PSQ 96MD
system with the PyroGold SQA Reagent Kit (Pyrosequencing) and
results were analyzed using the Q-CpG software (V.1.0.9,
Pyrosequencing AB). From the original 30 different pyrosequenc-
ing amplicons, we discarded those that did not have complete data
for all 16 pairs. For the 17 remaining amplicons (7 hyper-MVPs,
10 hypo-MVPs) we calculated the mean difference between all
CpGs in the amplicon for all T1D vs. all normal samples in the set.
Analysis of T1D–MVPs in independent MZ pairs and
pre/post–T1D and Ab+/T1D–singletons
Mean methylation differences associated with each T1D–MVP
for which complete data was available (Table S2) were calculated
between 4 T1D–discordant MZ pairs not included in the original
dataset, or between 4 Ab+/T1D–singletons and 9 singletons
representing the control pair. This yields a single overall
methylation difference for each T1D–MVP. Significance of
differences between hyper- and hypo-MVPs was determined by
Welch’s t-tests between scores associated with hyper-MVPs and
scores associated with hypo-MVPs.
For the pre/post–T1D samples, we compared methylation in
pre/post–T1D samples and controls using one-sided Wilcoxon
rank sum tests, with the alternative hypothesis defined so that
direction of methylation difference between pre/post and control
samples was the same as between affected and unaffected MZ
pairs. The expected within MZ pair correlation causes the
variance to differ in the two groups when comparing pre/post
samples to controls, which is not allowed for using a rank sum test.
An alternative is to use a non-parametric test tailored to this
Behren’s-Fisher problem, and we found P values were similar
between the two tests where tests could be performed, but that the
rank sum tended to be conservative at smaller p values. However,
the nonparametric Behrens-Fisher statistic is not computable for
the most extreme scenarios, when all values in one group exceed
all values in another. Therefore we chose to use the rank sum test
in the knowledge results would be conservative. We used signed
rank tests to compare differences in pre and post–T1D samples. In
both cases, we summarized the evidence that there was differential
methylation using X=mean(2log(p)) with the mean taken over
the T1D–MVP sites. Under the null hypothesis, 2log(p) should
have an exponential distribution with mean 1, and X may
therefore be interpreted as the scale parameter describing this
exponential distribution, and values above 1 indicate smaller p
values than would be expected under the null. To avoid assuming
independence between T1D–MVP sites (an assumption which can
be problematic with array based assays), we estimated bootstrap
confidence intervals by re-sampling seven pre/post samples and
nine control MZ pairs with replacement 100,000 times.
Supporting Information
Figure S1 Comparison of Illumina27K profiles with bisulfite
PCR sequencing data from the Human Epigenome Project (HEP).
For every probe on the Illumina methylation array lying within
100 bp of an assayed region in the HEP bisulfite dataset, we
compared the mean Illumina Beta score across the control CD4
samples to the mean HEP methylation level averaged across all
CpG sites lying within 100 bp of the Illumina probe. The
correlation between the two datasets is R2 = 0.88 (Pearson’s).
(DOC)
Figure S2 FACS analysis for CD14+ purity following Magnetic
Activated Cell Sorting (MACS) enrichment. From each MACS-
enriched CD14+ monocyte cell sample, we took two aliquots
(16105 cells in each case) and stained with either mouse IgG as a
negative control (A) or CD14+ FITC (C). CD14+ percentage purity
was then determined by FACS analysis on gated P2 as shown in
(B) for the mouse IgG aliquot, and (D) for the CD14+ FITC
aliquot. Percentage purity for each case is shown in the tables on
right for both. Overall percentage purity of CD14+ cells observed
typically ranged from 90–95% (refer to ‘P2’ %Parent values listed
in the table). Shown is a representative example (T1Dpair8-
affected).
(DOC)
Figure S3 Pyrosequencing validation of T1D–MVPs. Mean
methylation differences between 15 diabetics and their healthy
twins in bisulfite-pyrosequencing amplicons around hypo-MVPs
(n= 8) and hyper-MVPs (n= 5). Bars indicate 50% bootstrap
confidence intervals on the means, and whiskers indicate 95%
confidence intervals on the means.
(DOC)
Table S1 Sample information.
(DOC)
Table S2 List of T1D–MVPs called at P,0.01. T1D–MVPs
were called in the 15 T1D–discordant MZ pairs using pairwise T-
tests as described in the Supplementary Methods (above). The
CpG ID is the Illumina27K probe reference for the CpG in
question. HypoT1D–MVPs are coloured in yellow and Hy-
poerT1D–MVPs in blue. P-values are derived from pairwise T-
tests. The methylation values = 100*(Beta value of affected twin –
beta value of unaffected twin).
(DOC)
Table S3 Pyrosequencing analysis of selected T1D–MVPs. Only
the 13 different reactions for which we obtained data for all
samples are shown. Blue =Hyper-T1D–MVPs and Yellow= -
Hypo-T1D–MVPs.
(DOC)
Table S4 Independent replication and establishment of the
temporal origins of T1D–MVPs. For each T1D–MVP, we used
Wilcoxon rank sum tests to compare methylation in seven pre-/
post–T1D diagnosis samples to 18 samples from the nine
unaffected MZ control pairs (see Methods). Under the null
hypothesis, the 2log(p) values from this test follow an exponential
distribution, with scale parameter 1; values above 1 indicate that p
values tend to be smaller than expected under the null. The table
shows the estimated scale parameter, bootstrap 95% confidence
intervals and one-sided P values calculated by inverting the one
sided bootstrap confidence interval with leftmost limit equal to one
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(i.e. with an alternative hypothesis defined by smaller p values than
expected under the null) derived from 100,000 bootstraps.
(DOC)
Table S5 List of primers used in the pyrosequencing assays.
(DOC)
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